These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 26926468)

  • 21. Advances in the development of hybrid anticancer drugs.
    Fortin S; Bérubé G
    Expert Opin Drug Discov; 2013 Aug; 8(8):1029-47. PubMed ID: 23646979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets.
    Sumi NJ; Ctortecka C; Hu Q; Bryant AT; Fang B; Remsing Rix LL; Ayaz M; Kinose F; Welsh EA; Eschrich SA; Lawrence HR; Koomen JM; Haura EB; Rix U
    Cell Chem Biol; 2019 Sep; 26(9):1240-1252.e11. PubMed ID: 31257184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A systematic analysis of FDA-approved anticancer drugs.
    Sun J; Wei Q; Zhou Y; Wang J; Liu Q; Xu H
    BMC Syst Biol; 2017 Oct; 11(Suppl 5):87. PubMed ID: 28984210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topoisomerases as anticancer targets.
    Delgado JL; Hsieh CM; Chan NL; Hiasa H
    Biochem J; 2018 Jan; 475(2):373-398. PubMed ID: 29363591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.
    Liu T; Wan Y; Xiao Y; Xia C; Duan G
    J Med Chem; 2020 Sep; 63(17):8977-9002. PubMed ID: 32320239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overview on the current status of virtual high-throughput screening and combinatorial chemistry approaches in multi-target anticancer drug discovery; Part I.
    Geromichalos GD; Alifieris CE; Geromichalou EG; Trafalis DT
    J BUON; 2016; 21(4):764-779. PubMed ID: 27685895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA topoisomerases as anticancer drug targets: from the laboratory to the clinic.
    Holden JA
    Curr Med Chem Anticancer Agents; 2001 May; 1(1):1-25. PubMed ID: 12678768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation.
    Omae K; Kataoka Y; Tsujimoto Y; Tsutsumi Y; Yamamoto Y; Fukuhara S; Furukawa TA
    BMC Cancer; 2019 Oct; 19(1):998. PubMed ID: 31651263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chromones: Privileged scaffold in anticancer drug discovery.
    Patil VM; Masand N; Verma S; Masand V
    Chem Biol Drug Des; 2021 Nov; 98(5):943-953. PubMed ID: 34519163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
    Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
    Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent advances in multitarget-directed ligands via in silico drug discovery.
    Maddeboina K; Yada B; Kumari S; McHale C; Pal D; Durden DL
    Drug Discov Today; 2024 Mar; 29(3):103904. PubMed ID: 38280625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ubiquitin-based anticancer therapy: carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors.
    Mattern MR; Wu J; Nicholson B
    Biochim Biophys Acta; 2012 Nov; 1823(11):2014-21. PubMed ID: 22610084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overview on Anticancer Drug Design and Development.
    Olgen S
    Curr Med Chem; 2018; 25(15):1704-1719. PubMed ID: 29189124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polypharmacology: in silico methods of ligand design and development.
    McKie SA
    Future Med Chem; 2016 Apr; 8(5):579-602. PubMed ID: 27105127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polypharmacology: promises and new drugs in 2022.
    Ryszkiewicz P; Malinowska B; Schlicker E
    Pharmacol Rep; 2023 Aug; 75(4):755-770. PubMed ID: 37278927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective.
    Zhang W; Bai Y; Wang Y; Xiao W
    Curr Pharm Des; 2016; 22(21):3171-81. PubMed ID: 26907941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medicinal polypharmacology: Exploration and exploitation of the polypharmacolome in modern drug development.
    Stefan SM; Rafehi M
    Drug Dev Res; 2024 Feb; 85(1):e22125. PubMed ID: 37920929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetics and oncology.
    Mummaneni P; Shord SS
    Pharmacotherapy; 2014 May; 34(5):495-505. PubMed ID: 24619798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors.
    Passeri D; Camaioni E; Liscio P; Sabbatini P; Ferri M; Carotti A; Giacchè N; Pellicciari R; Gioiello A; Macchiarulo A
    ChemMedChem; 2016 Jun; 11(12):1219-26. PubMed ID: 26424664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extended Multitarget Pharmacology of Anticancer Drugs.
    Shi D; Khan F; Abagyan R
    J Chem Inf Model; 2019 Jun; 59(6):3006-3017. PubMed ID: 31025863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.